Blog of Signaling Pathways

Interferon-γ increases sensitivity to chemotherapy and provides immunotherapy targets in models of metastatic castration-resistant prostate cancer

94 views | Apr 25 2022

Dimitrios Korentzelos et al. suggested that IFNγ might be useful in combinatorial regimens to induce sensitivity to immunotherapy and chemotherapy in hepatic metastases of mCRPC. [Read the Full Post]

Phase II Clinical and Translational Study of Everolimus ± Paclitaxel as First-Line Therapy in Cisplatin-Ineligible Advanced Urothelial Carcinoma

259 views | Apr 25 2022

Tomi Jun et al. thought that everolimus plus paclitaxel demonstrated clinical activity in cisplatin-ineligible patients with metastatic UC, although the specific contribution of everolimus could not be delineated. [Read the Full Post]

Proangiogenesis effects of compound danshen dripping pills in zebrafish

158 views | Apr 24 2022

Yang-Xi Hu et al. found that CDDP had a proangiogenic effect, the mechanism of which involved the VEGF/VEGFR and PI3K/AKT signaling pathways. [Read the Full Post]

Theratyping of the Rare CFTR Variants E193K and R334W in Rectal Organoid-Derived Epithelial Monolayers

333 views | Apr 24 2022

Fabiana Ciciriello et al. proposed that the functional CFTR assay might guide personalized medicine in patients with CF-like clinical manifestations as well as in those carrying rare CFTR mutations. [Read the Full Post]

Changes in Blood Cell Deformability in Chorea-Acanthocytosis and Effects of Treatment With Dasatinib or Lithium

177 views | Apr 23 2022

Felix Reichel et al. found that the need for a systematic assessment of the contribution of impaired blood cell mechanics to the clinical manifestation of ChAc. [Read the Full Post]

Individualization in the first-line treatment of advanced ovarian cancer based on the mechanism of action of molecularly targeted drugs

394 views | Apr 23 2022

Hidekatsu Nakai et al, found that the importance of achieving complete surgery and aiming for cure in the treatment of ovarian cancer and how the use of bevacizumab, olaparib, and niraparib should be individualized. [Read the Full Post]

Iguratimod Inhibits Skin Fibrosis by regulating TGF-β1/Smad Signaling Pathway in Systemic Sclerosis

328 views | Apr 22 2022

Xi Xie et al. indicated T614 inhibited dermal fibroblasts activation and skin fibrosis at least partly by regulating TGF-β1/smad pathway in experimental SSc models and might be a promising therapeutic agent for SSc. [Read the Full Post]

First-line therapy in non-small cell lung cancer patients with EGFR activating mutations: a consideration of the clinical position of osimertinib based on the subset of Japanese patients in the FLAURA study

228 views | Apr 22 2022

Yoko Tsukita et al. reviewed data from the randomized clinical trials of first-line EGFR-TKIs including a subset of Japanese patients and discussed first-line therapies for patients with NSCLC harbouring EGFR mutations. [Read the Full Post]

Novel immune-related signature based on immune cells for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma

99 views | Apr 21 2022

Libin Zhou et al.defined a robust signature that might be promising for predicting clinical outcomes and immunotherapy and targeted therapy response in ccRCC patients. [Read the Full Post]

A CT-based radiomics model to predict subsequent brain metastasis in patients with ALK-rearranged non-small cell lung cancer undergoing crizotinib treatment

382 views | Apr 21 2022

Yongluo Jiang et al. developed a CT-based radiomics model to predict subsequent BM in patients with non-brain metastatic NSCLC undergoing crizotinib treatment. [Read the Full Post]

Diet impacts triple-negative breast cancer growth, metastatic potential, chemotherapy responsiveness, and doxorubicin-mediated cardiac dysfunction

280 views | Apr 20 2022

Manuel U Ramirez et al. found that the Mediterranean diet might reduce lung metastatic lesions formation and prevent the development of cardiac toxicities. [Read the Full Post]

Clinically relevant CHK1 inhibitors abrogate wild-type and Y537S mutant ERα expression and proliferation in luminal primary and metastatic breast cancer cells

450 views | Apr 20 2022

Sara Pescatori et al. thought that CHK1 could be considered as an appealing novel pharmacological target for the treatment of luminal primary and MBCs. [Read the Full Post]

Nuclear translocation of p85β promotes tumorigenesis of PIK3CA helical domain mutant cancer

591 views | Apr 19 2022

Yujun Hao et al. found that the drug combination could be an effective therapeutic approach for PIK3CA helical domain mutant tumors. [Read the Full Post]

Sotorasib Tackles KRASG12C-Mutated Pancreatic Cancer

247 views | Apr 19 2022

Xinting Zheng et al. found that the mechanisms of resistance to sotorasib and determine the efficacy and safety of combination therapy for the treatment of NSCLC containing the KRAS G12C mutation. [Read the Full Post]

Partial response to dabrafenib and trametinib in relapsed BRAF V600E-Mutated multiple myeloma and possible mechanisms of resistance

160 views | Apr 18 2022

Tina Ernst et al. described a very good partial response and possible mechanisms of resistance to a combination of the BRAF inhibitor dabrafenib. [Read the Full Post]

Janus Kinase Inhibitors in the Treatment of Type I Interferonopathies: A Case Series From a Single Center in China

253 views | Apr 18 2022

Wendao Li et al. found that the JAK inhibitors baricitinib and tofacitinib were promising therapeutic agents for patients with SAVI, AGS, and SPENCD, especially for the improvement of cutaneous lesions and febrile attacks. [Read the Full Post]

Long-term Outcomes for Ibrutinib-Rituximab and Chemoimmunotherapy in CLL: Updated Results of the E1912 Trial

192 views | Apr 17 2022

Tait D Shanafelt et al. found that Ibrutinib-rituximab therapy offered superior PFS relative to FCR in both IGHV mutated and unmutated CLL patients as well as superior OS. [Read the Full Post]

CDK4/6 inhibitor enhances the radiosensitization of esophageal squamous cell carcinoma (ESCC) by activating autophagy signaling via the suppression of mTOR

168 views | Apr 17 2022

Wen-Jun Qin et al. found that palbociclib improved the radiosensitivity of ESCC in vivo and in vitro, and thus it might be a promising radiosensitization agent for the treatment of ESCC. [Read the Full Post]

Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

195 views | Apr 16 2022

Andrew J Armstrong et al.found that enzalutamide plus ADT significantly prolongs survival versus placebo plus ADT in patients with mHSPC. [Read the Full Post]

Erythrocyte-cancer Hybrid Membrane-camouflaged Mesoporous Silica Nanoparticles Loaded with Gboxin for Glioma-targeting Therapy

388 views | Apr 15 2022

Xiuxiu Jiao et al. found that the (MSNs/Gboxin)@[RBC-U] exhibited significant anti-cancer effected in vitro and the specific self-recognition to GBM cells. [Read the Full Post]